User:Kleinsorg/main

From 2010.igem.org

(Difference between revisions)
Line 88: Line 88:
}
}
 +
#desc-table {
 +
width:370px;
 +
height:170px;
 +
border: none;
 +
background:transparent;
 +
margin:10px 0px;
 +
}
 +
#desc {
#desc {
-
width:350px;
 
-
height:150px;
 
border: none;
border: none;
background:transparent;
background:transparent;
padding:0px;
padding:0px;
-
text-align:center;
+
text-align:justify;
-
align:center;
+
-
margin-top:-10px;
+
-
margin-bottom:-20px;
+
-
text-align:justify;
+
}
}
Line 230: Line 232:
</a>
</a>
-
<br><br><center>
+
<center><table id="desc-table"><tr><td><div id ="desc" border=0></div></td></tr></table></div></center>
-
<div id ="desc" border=0></div></center>
+
-
<br><br>
+
<a class="piclinks" href="javascript:writeText('You are working in bacteria and never heard of U2-OS, SREBP or CYP1A1? Dont worry! Browse our Eukaryopedia and enter the world of mammalian BioBricks. ')" onMouseOver="mouseOver(4)" onMouseOut="mouseOut(4)" onMouseDown="mouseDown(4)" onMouseUp="mouseUp(4)">
<a class="piclinks" href="javascript:writeText('You are working in bacteria and never heard of U2-OS, SREBP or CYP1A1? Dont worry! Browse our Eukaryopedia and enter the world of mammalian BioBricks. ')" onMouseOver="mouseOver(4)" onMouseOut="mouseOut(4)" onMouseDown="mouseDown(4)" onMouseUp="mouseUp(4)">

Revision as of 13:45, 30 September 2010

iGEM Heidelberg Mission 2010: miBricks


The key to successful gene therapy is integration of tissue specificity and fine-tuned target gene expression. The iGEM Team Heidelberg 2010 unlocks the world of synthetic microRNAs, since focusing solely on DNA has often been inconvenient for medical purposes. We engineered a toolkit for standardized measurements of interactions between artificial miRNAs and their binding sites. From this data we were able to compute an in silico model integrating binding site properties and knockdown percentages. Thus, the expression level of any gene of choice could be arbitrarily adjusted by employing the corresponding binding site design. To produce tissue specific miRNA gene shuttles, we developed an evolution-based method for synthesis of new adeno associated viruses. This enabled us to overcome the natural limitations of virus selectivity. In the future, miBricks could be applied for treatment of diseases like Diabetes and Hemophilia, opening the doors to new Synthetic Biology based medical approaches.










The iGEM 2010 Heidelberg - Team


Retrieved from "http://2010.igem.org/User:Kleinsorg/main"